A Phase 4 interventional study of Tegileridine and morphine in Scoliosis; Adolescence, Pain After Surgery and Analgesia, Patient-controlled, sponsored by Peking Union Medical College Hospital. Recruiting at 6 sites in China. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by Peking Union Medical College Hospital · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies in Scoliosis with a site in China — 22 open to participants now, 26 under way, none of them phase 3. Scoliosis · China.
Among the 55 studies in Scoliosis with a site in China, this one is the 11th largest by planned enrollment of the 37 interventional ones that give a count, is one of 5 that started in 2026, is one of 3 in phase 4, reaches primary completion later than 20 of the 25 other live ones, and was the 48th registered.
660 studies on the registry are indexed under Scoliosis; 185 are open to participants now.
Browse Scoliosis studies →22 of the 55 studies in Scoliosis with a site in China are open now. Recruiting first, the newest first:
Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 10–18
Second Affiliated Hospital of Wenzhou Medical University · Sites in China
Ages 10–15
Hangzhou Medical College · Sites in China
Ages 12–16
Peking Union Medical College Hospital · Sites in China
Ages 10–18
Second Affiliated Hospital of Wenzhou Medical University · Sites in China
Ages 6–15
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 117 Scoliosis studies recruiting now, 23 (20%) set no upper age limit and 88 (75%) stop at 75 or younger; 98 take children under 18; 14 take healthy volunteers.
This study: 10 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 171 is above the median of 45 across 386 interventional studies indexed under Scoliosis.
Median enrollment 100 across the 37 interventional studies, 200 across the 18 observational. Of the 24 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 55 has an industry lead sponsor. The 10 most frequent:
Peking Union Medical College Hospital is the lead sponsor of 1,158 studies on the registry; 477 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Peking Union Medical College Hospital has 3 studies filed under Scoliosis — fewer than ten, so there is no comparison to draw.
10 of the studies in Scoliosis with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06314594Hangzhou Medical CollegeProtocol for a Randomized Controlled Trial of a Clinician-Supervised Home-School-Hospital-Linked Digital Health Platform-Supported Conservative Management Pathway for AIS | 2026-11-30 |
| NCT07899294Jiawei JiangConstruction of a Screening and Precision Intervention System for Adolescent Idiopathic Scoliosis Based on the DIERS Spinal Moiré System | 2026-12 |
| NCT06470165Xuanwu Hospital, BeijingPriority-Matching Correction Technique in Degenerative Lumbar Scoliosis | 2026-12-31 |
| NCT06728046West China HospitalErector Spinae Plane Block v.s Patient Controlled Analgesia in Correction Surgery for Idiopathic Scoliosis | 2026-12-31 |
| NCT06506227The First Affiliated Hospital of Zhejiang Chinese Medical UniversityResearch on Key Technologies for Risk Prediction and Precise Diagnosis and Treatment of AIS Based on Epigene-phenotype | 2026-12-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 55 studies in Scoliosis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to see if a new pain medicine called Tegileridine is at least as effective as morphine (the standard treatment) for pain relief after spinal surgery in teenagers with scoliosis. This type of study is called a "non-inferiority" trial. The study will also carefully compare the safety of both medicines.
The main questions it aims to answer are:
Is Tegileridine no worse than morphine at controlling pain in the first 24 hours after surgery? How do the side effects (like sleepiness or nausea) of Tegileridine compare to those of morphine? Researchers will compare two different doses of Tegileridine against morphine. Neither the participants nor the doctors assessing them will know which medicine is being given.
Participants in this study will:
Receive one of the three pain medicine options through a pump (called a PCA pump) that they can control themselves after surgery.
Use the pump for up to 48 hours. Regularly rate their pain levels using a simple number scale. Have their health closely monitored by the study team during this time.
This is a prospective, multicentre, randomized, double-blind, controlled, non-inferiority clinical trial designed to evaluate the efficacy and safety of Tegileridine for postoperative analgesia in adolescent patients undergoing spinal fusion surgery for scoliosis.
Postoperative pain management is crucial for recovery, with opioids like morphine being the standard of care. However, morphine is associated with significant side effects, including respiratory depression, nausea, and vomiting. Tegileridine is a novel, highly selective μ-opioid receptor agonist that is hypothesized to provide potent analgesia with an improved safety profile, particularly regarding respiratory depression.
A total of 171 adolescent patients (aged 10 to \<18 years) scheduled for surgery will be enrolled. Participants will be randomly assigned in a 1:1:1 ratio to one of three treatment groups:
Group T1: Tegileridine 20 μg/kg loading dose, followed by patient-controlled analgesia (PCA) at a dose of 1 μg/kg per bolus.
Group T2: Tegileridine 20 μg/kg loading dose, followed by PCA at a dose of 2 μg/kg per bolus.
Group M (Active Comparator): Morphine 60 μg/kg loading dose, followed by PCA at a dose of 20 μg/kg per bolus.
The study medication will be prepared by an unblinded nurse not involved in subsequent patient care or assessment. Upon arrival in the post-anesthesia care unit (PACU) after surgery, the assigned loading dose of the study drug will be administered, immediately followed by the initiation of the PCA pump, which will be maintained for 48 hours. To maintain blinding, the study drugs are diluted in normal saline to appear identical. Patients, attending anesthesiologists, and outcome assessors will all be blinded to the treatment assignment.
The primary objective is to demonstrate the non-inferiority of Tegileridine to morphine in terms of analgesic efficacy. The primary efficacy endpoint is the area under the curve (AUC) of resting pain intensity scores, measured on an 11-point Numerical Rating Scale (NRS), over the first 24 hours after initiating PCA. A predefined non-inferiority margin of 12 will be used for the comparison. Statistical testing will follow a hierarchical procedure, first comparing the T2 group to the morphine group, and if non-inferiority is established, proceeding to compare the T1 group to morphine.
Secondary objectives include comparing the groups on various efficacy measures, such as pain AUC at other time points, rescue analgesic consumption, and patient satisfaction. Safety objectives focus on the incidence and severity of adverse events, with continuous monitoring for postoperative hypoxemia (SpO₂ \< 90%), assessment of sedation levels using the modified Pasero Opioid-induced Sedation Scale (m-POSS), and recording of other common opioid-related side effects like postoperative nausea and vomiting (PONV).
The primary analysis will be conducted on the Full Analysis Set (FAS) and Per-Protocol Set (PPS). Sensitivity analyses and a pre-specified subgroup analysis by gender are also planned.
The criteria were revised on the registry on Oct 13, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this arm will receive an initial intravenous loading dose of 20 μg/kg Tegileridine upon transfer to the post-anesthesia care unit (PACU), immediately followed by postoperative patient-controlled analgesia (PCA). The PCA solution is prepared by diluting Tegileridine in normal saline to a total volume of 200 ml. The PCA pump is programmed to deliver a bolus dose of 1 μg/kg Tegileridine per activation, with a 10-minute lockout interval and no background infusion. PCA therapy will be maintained for at least 48 hours, barring any adverse events requiring discontinuation.
Drug: Tegileridine
Participants in this arm will receive an initial intravenous loading dose of 20 μg/kg Tegileridine upon transfer to the post-anesthesia care unit (PACU), immediately followed by postoperative patient-controlled analgesia (PCA). The PCA solution is prepared by diluting Tegileridine in normal saline to a total volume of 200 ml. The PCA pump is programmed to deliver a bolus dose of 2 μg/kg Tegileridine per activation, with a 10-minute lockout interval and no background infusion. PCA therapy will be maintained for at least 48 hours, barring any adverse events requiring discontinuation.
Drug: Tegileridine
Participants in this arm will receive an initial intravenous loading dose of 60 μg/kg morphine upon transfer to the post-anesthesia care unit (PACU), immediately followed by postoperative patient-controlled analgesia (PCA). The PCA solution is prepared by diluting morphine in normal saline to a total volume of 200 ml. The PCA pump is programmed to deliver a bolus dose of 20 μg/kg morphine per activation, with a 10-minute lockout interval and no background infusion. PCA therapy will be maintained for at least 48 hours, barring any adverse events requiring discontinuation.
Drug: morphine
Tegileridine is a novel μ-opioid receptor-biased agonist. In this study, it is administered as an initial intravenous loading dose immediately followed by patient-controlled analgesia (PCA) for postoperative pain management. The PCA solution is prepared by diluting the Tegileridine injection in normal saline.
Morphine is a standard opioid analgesic used as the active comparator in this study. It is administered as an initial intravenous loading dose immediately followed by patient-controlled analgesia (PCA) for postoperative pain management. The PCA solution is prepared by diluting Morphine injection in normal saline.
Area Under the Curve (AUC) of Resting Pain Scores on the 11-point Numerical Rating Scale (NRS) Over the First 24 Hours Postoperative
The analgesic efficacy will be assessed by calculating the Area Under the Curve (AUC) of the resting pain intensity scores over the first 24 hours after initiating Patient-Controlled Analgesia (PCA). Pain Intensity Measurement: Pain intensity is assessed by the participant using an 11-point Numerical Rating Scale (NRS), where 0 represents "no pain" and 10 represents "the worst pain imaginable." Resting state is defined as being in a stationary position without active movement. Assessment Time Points: NRS scores are recorded at predefined time points: 5 minutes, 10 minutes, 15 minutes, 30 minutes, 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 18 hours, and 24 hours after the end of the loading dose infusion. AUC Calculation: The AUC for the NRS scores versus time is calculated using the trapezoidal rule, which sums the areas of trapezoids formed between consecutive time points. A lower AUC indicates better and more sustained pain control over the 24-hour period.
Time frame: From the end of the loading dose infusion up to 24 hours.
Area Under the Curve (AUC) of Resting Pain Scores on the Numerical Rating Scale (NRS) Over Multiple Time Intervals
The AUC of resting pain intensity scores (measured on an 11-point NRS, where 0 represents "no pain" and 10 represents "the worst pain imaginable") will be calculated using the trapezoidal rule. The AUC will be calculated for the following cumulative time intervals after the end of the loading dose infusion: 0-6 hours, 0-12 hours, and 0-48 hours. A lower AUC indicates better and more sustained pain control over the specified period.
Time frame: The AUC will be calculated for the cumulative intervals from the end of the loading dose infusion up to 6 hours, 12 hours, and 48 hours.
Area Under the Curve (AUC) of Activity-Induced Pain Scores on the Numerical Rating Scale (NRS) over Multiple Intervals
The AUC of pain intensity scores during activity (or coughing) measured on an 11-point NRS will be calculated over the intervals of 0-6 hours, 0-12 hours, 0-24 hours, and 0-48 hours after the end of the loading dose infusion. The AUC is calculated using the trapezoidal rule.
Time frame: Assessed at 6, 12, 24, and 48 hours after the end of the loading dose infusion.
Resting and Activity-Induced Pain Scores on the Numerical Rating Scale (NRS) at Multiple Time Points
Pain intensity will be assessed using the 11-point NRS (0=no pain, 10=worst pain imaginable) at rest and during activity (or coughing) at the following time points after the end of the loading dose infusion: 5 minutes, 10 minutes, 15 minutes, 30 minutes, 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 18 hours, 24 hours, 30 hours, 36 hours, 42 hours, and 48 hours.
Time frame: Assessed at 16 predefined time points from 5 minutes to 48 hours after the end of the loading dose infusion.
Proportion of Participants Requiring Rescue Analgesia
The percentage of participants who receive rescue analgesia during the PCA treatment period. Rescue analgesia is defined as the administration of additional analgesic medication (e.g., acetaminophen, NSAIDs, or other opioids) when the participant's pain is not adequately controlled (NRS score ≥4) despite receiving the study drug.
Time frame: From the end of the loading dose infusion up to 48 hours.
Time to First Use of Rescue Analgesia
The time elapsed from the end of the loading dose infusion to the first administration of any rescue analgesic medication.
Time frame: From the end of the loading dose infusion up to 48 hours (time to event is measured).
Total Number of Rescue Analgesic Administrations Per Participant
The total count of rescue analgesic medication administrations required for each participant during the PCA treatment period, when pain was not controlled (NRS ≥4) by the study drug.
Time frame: From the end of the loading dose infusion up to 48 hours.
Cumulative Dose of Rescue Analgesic Medication
The total cumulative dose of all rescue analgesic medications used by each participant during the PCA treatment period. Doses of different opioids will be converted to morphine milligram equivalents (MME) for summation.
Time frame: From the end of the loading dose infusion up to 48 hours.
Proportion of Participants with Pain NRS Score ≤ 3 at Each Assessment Time Point
The percentage of participants who achieve a pain intensity score of 3 or less (indicating mild pain) on the 11-point NRS at the following time points after the end of the loading dose infusion: 5 minutes, 10 minutes, 15 minutes, 30 minutes, 2 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 18 hours, 24 hours, 30 hours, 36 hours, 42 hours, and 48 hours.
Time frame: Assessed at 16 predefined time points from 5 minutes to 48 hours after the end of the loading dose infusion.
Total Number of PCA Pump Attempts and Successful Deliveries
The total number of demands (attempts) made by the participant on the PCA pump and the total number of successful drug deliveries (effective deliveries) recorded by the pump during the treatment period.
Time frame: From the end of the loading dose infusion up to 48 hours.
Postoperative Length of Hospital Stay
The duration of hospitalization after the surgical procedure, measured from the day of surgery until the day of discharge.
Time frame: From the day of surgery to the day of hospital discharge, an average of 10 days.
Satisfaction with Pain Treatment
Participants' satisfaction with pain management is assessed using an 11-point numerical scale (0=extremely dissatisfied, 10=extremely satisfied) within 30 minutes after the cessation of PCA therapy.
Time frame: At 30 minutes after stopping PCA (typically around 48 hours post-surgery).
Incidence of Postoperative Hypoxemia
The proportion of participants experiencing postoperative hypoxemia, defined as a percutaneous oxygen saturation (SpO2) reading below 90%, as monitored by pulse oximetry during the PCA treatment period.
Time frame: From the end of the loading dose infusion up to 48 hours.
Incidence and Severity of Postoperative Nausea and Vomiting (PONV)
The occurrence and severity of PONV assessed by healthcare personnel using a Visual Analog Scale (VAS) for nausea/vomiting (0=no nausea/vomiting, 10=worst imaginable nausea/vomiting) at specified time points. Severity is categorized as mild (VAS\<4cm), moderate (VAS 4-7cm), or severe (VAS\>7cm).
Time frame: Assessed at 5 minutes, 10 minutes, 30 minutes, 6 hours, 12 hours, 18 hours, 24 hours, 36 hours, and 48 hours after the end of the loading dose infusion.
Level of Sedation as Assessed by the Modified Pasero Opioid-Induced Sedation Scale (m-POSS)
The level of sedation is assessed by healthcare personnel using the m-POSS, which includes scores from S (sleep, easily aroused) to 4 (somnolent, minimal or no response to stimulus). Higher scores indicate deeper sedation.
Time frame: Assessed at 5 minutes, 10 minutes, 30 minutes, 6 hours, 12 hours, 18 hours, 24 hours, 36 hours, and 48 hours after the end of the loading dose infusion.
Incidence of Other Adverse Events
The occurrence of other predefined adverse events during the treatment period, including abdominal pain, abdominal distension (time to first flatus and defecation), fever, dizziness, headache, sinus bradycardia, somnolence, and pruritus.
Time frame: From the end of the loading dose infusion up to 48 hours.
Plan to share: Yes — Deidentified individual participant data (IPD), alongside the study protocol, statistical analysis plan, and analytic code, will be available via a controlled-access process. Access will be granted to qualified researchers with methodologically sound proposals from 6 to 36 months following primary publication. Requesters must contact the corresponding author and sign a formal Data Access Agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: Beginning 6 months and ending 3 years after the publication of results
Access criteria: Access to deidentified Individual Participant Data (IPD) will be granted to qualified academic and clinical researchers. To qualify, researchers must submit a methodologically sound research proposal (e.g., for IPD meta-analysis) alongside a detailed statistical analysis plan. Requests will be reviewed by the Principal Investigator and the trial steering committee. Proposals will be evaluated based on scientific merit, methodological rigor, and ethical appropriateness. As the mechanism for data sharing, approved requesters must sign a formal Data Access Agreement (DAA). The DAA strictly limits data use to the approved analytical protocol, completely prohibits any attempts to re-identify participants, and legally binds the requesters to protect adolescent privacy. Requests should be directed to the corresponding author via email. The data will be accessible from 6 to 36 months following the publication of the primary trial results.
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Oct 2027, 18 months after the start.
Of 19 phase 4 interventional studies under Scoliosis, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 37. This study's planned 18 months is close to that.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: start Jul 2026 → Apr 2026, primary completion Jun 2027 → Oct 2027 and completion Sep 2027 → Dec 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tegileridine
Peking Union Medical College Hospital →